Key takeaways
- Publications and patents are the clearest public record of what a company is actually researching and where its science is heading.
- A filing in a therapeutic area a company was not in before, or a rising pace of filings across its portfolio, shows it moving into something new.
- Reading that direction early is the edge: you reach the account understanding its science, while rivals are still waiting for a press release.
- This tells you where an account is going, not that a purchase is signed this quarter, and that direction is exactly what makes your outreach land.
Publications and patents are the clearest public record of what a life science company is actually researching. A paper shows what a team is working on and thinks is worth putting its name to. A patent shows what a company believes is valuable enough to protect. Read together, across an account, they tell you where its science is pointed and where it is expanding, which is exactly the kind of understanding that lets you reach an account with the right context and the right timing, before rival vendors even notice the direction has changed.
What publication and patent activity reveals about an account
Every paper and every filing is a piece of what a company is genuinely spending its research effort on. Taken one at a time they read as routine. Taken together, and watched over time, they map an account's scientific direction: the programs it is investing in, the problems it is trying to solve, and the areas it is starting to move into.
Two patterns say the most about where an account is heading. The first is a filing in a therapeutic area a company was not working in before. That is expansion, not upkeep: it implies the company is pushing into new scientific territory, the kind of move that usually comes before the hiring, the trial activity, and the program announcements that eventually make the new direction obvious. The second is a rising pace of filings across the whole portfolio. When a company is filing and getting patents granted noticeably faster than its own past pattern, the tempo of its research is picking up, and something inside the organization is scaling up even if it is not yet clear exactly where. Both tell you an account is on the move, and in roughly which direction, while that is still your knowledge and not the market's.
Why this signal is reliable
Publications and patents work because they are public record, and because they are what a company actually did rather than what it says about itself. Scientific literature and patent filings are both open: a paper's author affiliation and a patent's named assignee point back to a company, and a paper's author list points back to a specific person, so the activity can be tied to the accounts and contacts you care about.
That grounding is what makes this trustworthy. A company can shape a press release, but a filing is a dated, documented commitment, and a published paper has been through review and put out under real names. You are reading evidence of the work itself, not marketing around it, which is why a picture built from publications and patents holds up better than an inference drawn from softer signals.
The edge: reading a company's direction before your competitors do
Here is where this signal earns its keep. Most vendors wait for the loud moments: the funding headline, the executive hire, the program launch, the open evaluation. Those moments are real, but by the time they land, every seller in the category is looking at the same account on the same day, and you are competing to say something the buyer has already heard five times.
Publications and patents come earlier. A new therapeutic area shows up in a filing before it shows up in a job posting; a rising research tempo is visible in the portfolio before it is announced. If you are reading that activity, you can reach the account already understanding its science and pointed at where it is going, while your competitors are still waiting for the news that tells them to pay attention. That is the whole advantage: not just knowing an account exists, but understanding its direction early enough to shape and time your approach around it, ahead of the crowd that shows up once the shift is public.
What you are blind to without it
Skip this signal and you are working from an account's public face: what it does today, broadly, and whatever it has chosen to announce. What you cannot see is movement. You will not know that a company just started filing in an area it never touched before, or that its research is quietly accelerating, until those changes surface as news, and by then your window to be early is gone.
The cost is showing up either generic or late. Generic, because you are talking to an account without understanding what it is actually working on now. Late, because you find out about its new direction at the same moment as everyone else. Reading publications and patents is how you close that gap: it keeps you current on what an account is truly doing, so your outreach is built on where the account is heading rather than where it was. For how this fits with the timing of every other signal, see timing outreach with readiness signals.
Where this fits in the bigger picture
Publications and patents are the direction-setting layer of a fuller signal picture. Read alongside funding, clinical, regulatory, and hiring activity, they tell you what an account is working toward, while those other signals tell you it now has the means or the momentum to act. Understanding the direction is what makes the rest legible: you know not just that something is happening at an account, but what it is about.
See buying signals in biotech and pharma for how the signal types work together, and how to prioritize accounts for where account fit and signals come together to decide who you focus on. For quick definitions of every signal type mentioned here, see the life science sales signals glossary.